Associate Professor MedStar Washington Hospital Center, United States
Interventional Oncology is in the midst of rapid evolution, with multiple phase II/III clinical trials poised to define the role of IR therapies across tumor types. This session will highlight active and upcoming IO trials, organized by disease focus—including liver, lung, renal, metastases, and emerging or competitive spaces. Faculty will synthesize the major studies within their area, providing attendees with a clear roadmap of the current IO research landscape and insight into the pivotal results expected to shape practice in the near future.
Learning Objectives:
Identify key IO clinical trials across major disease categories (liver, lung, renal, metastases, and new indications).
Understand how ongoing and upcoming phase II/III trials may influence patient selection and multidisciplinary cancer care.
Anticipate the impact of emerging and competitive trial data on the future role of Interventional Oncology.
